Cancer Clinical Trial -EPIK-O-20156

A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (CBYL719K12301)

Drug

TAXOL vs. Olaparib and alpesib

Phase

Phase III

Condition

Ovarian, Peritoneal

Keywords

No germline BRCA1/2 mutation Platinum-resistant, Platinum refractory